• Iovance posted 2Q26 revenue of USD 99.31 million, up 66% year over year, driven by continued U.S. Amtagvi demand.
• Operating loss narrowed to USD 51.91 million from USD 113.77 million a year earlier; net loss improved to USD 47.32 million from USD 111.66 million.
• Gross margin rose to 56%, reflecting higher Amtagvi volume, cost optimization, and maturing internal manufacturing efficiencies.
• U.S. Amtagvi revenue reached about USD 91 million; global Proleukin revenue was about USD 9 million, expected to grow through 2026.
• Management is reviewing 2026 revenue guidance of USD 350 million to USD 370 million, with an update planned in 3Q; FDA granted Fast Track for lifileucel in soft tissue sarcomas.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Iovance Biotherapeutics Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.